Skip to main content
Atrás
NVAX logo

Novavax, Inc.

Calidad de datos: 100%
NVAX
NASDAQ Healthcare Biotechnology
$9.72
▲ $0.10 (1.04%)
Cap. Mercado: 1.58B
Rango del Día
$9.44 $10.00
Rango de 52 Semanas
$5.01 $11.97
Volumen
4,462,562
Promedio 50D / 200D
$9.23 / $7.97
Cierre Anterior
$9.62

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 3.6 0.4
P/B 2.9
ROE % 3.7
Net Margin % 39.2 3.8
Rev Growth 5Y % 54.4 10.0
D/E 0.2

Puntos Clave

Revenue grew 54.42% annually over 5 years — strong growth
Net margin of 39.19% shows strong profitability
Negative free cash flow of -250.20M
P/E of 3.60 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10.27%
Capital efficient — spends only 0.49% of revenue on capex

Crecimiento

Revenue Growth (5Y)
54.42%
Revenue (1Y)64.69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROIC348.97%
Net Margin39.19%
Op. Margin50.14%

Seguridad

Debt / Equity
N/A
Current Ratio2.13
Interest Coverage24.98

Valoración

P/E Ratio
3.60
P/B RatioN/A
EV/EBITDA2.83
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64.69% Revenue Growth (3Y) 42.10%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 54.42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.12B Net Income (TTM) 440.30M
ROE N/A ROA 37.42%
Gross Margin 93.67% Operating Margin 50.14%
Net Margin 39.19% Free Cash Flow (TTM) -250.20M
ROIC 348.97% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.13
Interest Coverage 24.98 Dividend Yield 0.00%
Valuation
P/E Ratio 3.60 P/B Ratio N/A
P/S Ratio 1.41 PEG Ratio -0.01
EV/EBITDA 2.83 Dividend Yield 0.00%
Market Cap 1.58B Enterprise Value 1.59B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.12B 682.16M 556.38M 1.60B 197.58M
Net Income 440.30M -187.50M -545.06M -657.94M -1.74B
EPS (Diluted) 2.54 -1.23 -5.41 -8.42 -23.44
Gross Profit 1.05B 479.42M 212.61M 696.31M 197.58M
Operating Income 563.27M -248.93M -566.51M -644.74M -1.69B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.18B 1.56B 1.80B 2.26B 2.58B
Total Liabilities 1.30B 2.18B 2.51B 2.89B 2.93B
Shareholders' Equity -127.75M -623.84M -716.93M -634.08M -351.67M
Total Debt 248.81M 230.42M 229.08M 549.78M 453.99M
Cash & Equivalents 240.63M 530.23M 568.51M 1.34B 1.52B
Current Assets 978.28M 1.13B 1.14B 1.70B 2.16B
Current Liabilities 459.95M 1.15B 1.64B 2.46B 2.39B